Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- PennyStockEarnings Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is On: Theravance Inc (NASDAQ:THRX), Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), Geron Corporation (NASDAQ:GERN), Humana Inc (NYSE:HUM)
Theravance Inc (NASDAQ:THRX) moved up +2.18% and closed at $42.10 in the last trading session with the overall traded volume of 1.87 million shares, more versus the average volume of 643,247 shares. Its 52 weeks high price was $42.96 and suffered lowest price of $19.61 in the same period.
It has market cap of $4.65 billion while its total outstanding shares are 110.50 million. Its stock’s 3 months performance stands at +23.39%. Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain.
Will THRX Continue To Move Higher? Find Out Here
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) no change with the closing price of $2.86. The overall volume in the last trading session was 1.79 million shares. Its fifty two week range was $0.37-$2.99. The total market capitalization remained $151.28 million.
The stock gained +557.47% in this year and reported the increase of +17.70% in the last 5 days. In its share capital, the company has 52.89 million outstanding shares. Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders.
Is CPRX a Solid Investment at These Levels? Read This Report For Details
Geron Corporation (NASDAQ:GERN) decreased -6.79% to close at $2.47 in the last trading session and its total traded volume was 1.80 million shares, beating the average volume of 1.13 million. The company has market cap of $317.76 million.
The stock has positive year-to-date performance of +69.18% while its quarterly performance remained +122.52%. Geron Corporation is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Why Should Investors Buy GERN After the Recent Fall? Just Go Here and Find Out
Humana Inc (NYSE:HUM) jumped +0.87% to closed at $95.53 and its overall volume in the last trading session was 1.78 million shares, beating the average volume of 906,646. It has market cap of $14.95 billion while its total outstanding shares are 156.46 million.
The stock gained +41.50% in this year and reported the loss of -2.76% in the last 5 days. Its 3 months performance stands at +14.23%. Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being.
Why Should Investors Buy HUM After The Recent Gain? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)